Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 142
Filter
1.
Expert Opin Drug Metab Toxicol ; 16(3): 255-274, 2020 Mar.
Article in English | MEDLINE | ID: mdl-32129111

ABSTRACT

Introduction: This Experts' opinion provides an updated scientific support to gynecologists, obstetricians, endocrinologists, nutritionists, neurologists and general practitioners on the use of Inositols in the therapy of Polycystic Ovary Syndrome (PCOS) and non-insulin dependent (type 2) diabetes mellitus (NIDDM).Areas covered: This paper summarizes the physiology of Myo-Inositol (MI) and D-Chiro-Inositol (DCI), two important molecules present in human organisms, and their therapeutic role, also for treating infertility. Some deep differences between the physiological functions of MI and DCI, as well as their safety and intestinal absorption are discussed. Updates include new evidence on the efficacy exerted in PCOS by the 40:1 MI/DCI ratio, and the innovative approach based on alpha-lactalbumin to overcome the decreased therapeutic efficacy of Inositols in some patients.Expert opinion: The evidence suggests that MI, alone or with DCI in the 40:1 ratio, offers a promising treatment for PCOS and NIDDM. However, additional studies need to evaluate some still unresolved issues, such as the best MI/DCI ratio for treating NIDDM, the potential cost-effectiveness of reduced gonadotropins administration in IVF due to MI treatment, or the benefit of MI supplementation in ovulation induction with clomiphene citrate in PCOS patients.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Expert Testimony , Inositol/therapeutic use , Polycystic Ovary Syndrome/drug therapy , Reproduction/drug effects , Vitamin B Complex/therapeutic use , Animals , Diabetes Mellitus, Type 2/metabolism , Expert Testimony/trends , Female , Humans , Inositol/pharmacokinetics , Polycystic Ovary Syndrome/metabolism , Reproduction/physiology , Vitamin B Complex/pharmacokinetics
2.
Curr Vasc Pharmacol ; 17(6): 610-617, 2019.
Article in English | MEDLINE | ID: mdl-30963976

ABSTRACT

Vitamin D and calcium are considered crucial for the treatment of bone diseases. Both vitamin D and calcium contribute to bone homeostasis but also preserve muscle health by reducing the risk of falls and fractures. Low vitamin D concentrations result in secondary hyperparathyroidism and contribute to bone loss, although the development of secondary hyperparathyroidism varies, even in patients with severe vitamin D deficiency. Findings from observational studies have shown controversial results regarding the association between bone mineral density and vitamin D/calcium status, thus sparking a debate regarding optimum concentrations of 25-hydroxyvitamin D and calcium for the best possible skeletal health. Although most of the intervention studies reported a positive effect of supplementation with calcium and vitamin D on bone in patients with osteoporosis, this therapeutic approach has been a matter of debate regarding potential side effects on the cardiovascular (CV) system. Thus, the aim of this review is to consider the current evidence on the physiological role of vitamin D and calcium on bone and muscle health. Moreover, we provide an overview on observational and interventional studies that investigate the effect of vitamin D and calcium supplementation on bone health, also taking into account the possible CV side-effects. We also provide molecular insights on the effect of calcium plus vitamin D on the CV system.


Subject(s)
Bone Remodeling/drug effects , Calcium/therapeutic use , Cardiovascular Diseases/prevention & control , Cardiovascular System/drug effects , Hyperparathyroidism, Secondary/drug therapy , Osteoporosis/drug therapy , Vitamin D Deficiency/drug therapy , Vitamin D/therapeutic use , Animals , Biomarkers/blood , Calcium/adverse effects , Calcium/blood , Cardiovascular Diseases/blood , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/physiopathology , Cardiovascular System/metabolism , Cardiovascular System/physiopathology , Dietary Supplements/adverse effects , Humans , Hyperparathyroidism, Secondary/blood , Hyperparathyroidism, Secondary/epidemiology , Hyperparathyroidism, Secondary/physiopathology , Osteoporosis/blood , Osteoporosis/epidemiology , Osteoporosis/physiopathology , Osteoporotic Fractures/epidemiology , Osteoporotic Fractures/physiopathology , Osteoporotic Fractures/prevention & control , Risk Factors , Treatment Outcome , Vitamin D/adverse effects , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/epidemiology , Vitamin D Deficiency/physiopathology
3.
Hormones (Athens) ; 18(1): 75-84, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30644069

ABSTRACT

AIM: The objective of this study was to investigate the effect of implementation of short-term patient empowerment as applied to Mediterranean diet (MD) adherence on metabolic and anthropometric parameters in prediabetic overweight or obese subjects. METHODS: The sample included 42 subjects with prediabetes, aged 18-75 years and with body mass index (BMI) > 25 kg/m2, who received dietary advice on MD by nutritionists during session groups every 2 weeks for 4 months. Data on energy caloric intake and macronutrient consumption were collected using a 7-day food diary record. Adherence to MD was investigated through the PREvención con DIeta MEDiterránea (PREDIMED) questionnaire. No advice was given regarding caloric restriction and physical activity. At baseline and at the end of the study, each subject underwent anthropometric, metabolic, and nutritional assessments. RESULTS: Approximately 40.5% of subjects had achieved restoration of normal glucose tolerance by the end of the study. Fasting plasma glucose, glycated hemoglobin (HbA1C), BMI, waist circumference, blood pressure, visceral adiposity index, triglycerides, and total and LDL cholesterol levels were significantly decreased, while HDL cholesterol had significantly increased by the end of the study. The subjects significantly increased adherence to MD, as assessed by the PREDIMED questionnaire at follow-up. A reduction of prevalence of the metabolic syndrome was also reported. Interestingly, the PREDIMED score correlated with HbA1C values at follow-up, after adjusting for BMI and total caloric intake. CONCLUSIONS: Implementation of short-term patient empowerment as applied to MD adherence was shown to improve anthropometric and metabolic parameters in prediabetic overweight or obese subjects. This is of considerable importance, given that diet must be the cornerstone of treatment in patients at high risk of developing type 2 diabetes.


Subject(s)
Diet, Mediterranean , Outcome Assessment, Health Care , Overweight/diet therapy , Patient Compliance/psychology , Patient Participation/methods , Prediabetic State/diet therapy , Psychotherapy, Brief/methods , Adolescent , Adult , Aged , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Obesity/diet therapy , Pilot Projects , Young Adult
4.
Endocrine ; 62(2): 292-298, 2018 11.
Article in English | MEDLINE | ID: mdl-30027433

ABSTRACT

INTRODUCTION: In both diabetic subjects and animal models high levels of vasopressin (AVP) have beendetected. The relationship between AVP and glucose metabolism is mediated through several direct andindirect effects and most of them are still unknown. METHODS: We have reviewed 100 manuscripts retrieved from Cochrane Library, Embase and Pubmeddatabases in order to highlight a possible relationship between copeptin and type 2 diabetes and to provideinsights on the molecular mechanism that could explain this association. RESULTS AND CONCLUSIONS: AVP potentiates CRH action at pituitary level resulting in an increased ACTH secretion and in turn in an increased cortisol secretion that escapes the negative feedback loop. Further, AVP regulates insulin and glucagon secretion through V1b receptor and promotes hepatic glycogenolysis and gluconeogenesis through V1a receptor. In addition to worsen glucose metabolism, AVP has been reported to have a role in the pathogenesis of diabetic complications such as cardiovascular diseases, kidney and ocular complications. Due to the very low concentration of AVP in the blood, the small size and poor stability, the assay of AVP is very difficult to perform. Thus, copeptin, the stable C-terminal portion of the prepro-vasopressin peptide has been identified as an easier assay to be measured and that mirrors AVP activity. Although there are promising evidence that copeptin could be involved in the pathogenesis of type 2 diabetes, further studies need to demonstrate the importance of copeptin as clinical marker to predict glucose metabolism derangements.


Subject(s)
Diabetes Mellitus, Type 2/prevention & control , Drinking/physiology , Glycopeptides/physiology , Animals , Arginine Vasopressin/blood , Biomarkers/blood , Diabetes Mellitus, Type 2/metabolism , Glucagon/blood , Glycopeptides/blood , Humans , Insulin/blood , Vasopressins/blood
5.
Nutr Res Rev ; 31(2): 291-301, 2018 12.
Article in English | MEDLINE | ID: mdl-30033891

ABSTRACT

High carbohydrate intake and low-grade inflammation cooperate with insulin resistance and hyperandrogenism to constitute an interactive continuum acting on the pathophysiology of polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age characterised by oligo-anovulatory infertility and cardiometabolic disorders. The role of insulin in PCOS is pivotal both in regulating the activity of ovarian and liver enzymes, respectively involved in androgen production and in triggering low-grade inflammation usually reported to be associated with an insulin resistance, dyslipidaemia and cardiometabolic diseases. Although an acute hyperglycaemia induced by oral glucose loading may increase inflammation and oxidative stress by generating reactive oxygen species through different mechanisms, the postprandial glucose increment, commonly associated with the Western diet, represents the major contributor of chronic sustained hyperglycaemia and pro-inflammatory state. Together with hyperinsulinaemia, hyperandrogenism and low-grade inflammation, unhealthy diet should be viewed as a key component of the 'deadly quartet' of metabolic risk factors associated with PCOS pathophysiology. The identification of a tight diet-inflammation-health association makes the adoption of healthy nutritional approaches a primary preventive and therapeutic tool in women with PCOS, weakening insulin resistance and eventually promoting improvements of reproductive life and endocrine outcomes. The intriguing nutritional-endocrine connections operating in PCOS underline the role of expert nutritionists in the management of this syndrome. The aim of the present review is to provide an at-a-glance overview of the possible bi-directional mechanisms linking inflammation, androgen excess and carbohydrate intake in women with PCOS.


Subject(s)
Androgens/blood , Blood Glucose/metabolism , Diet/adverse effects , Dietary Carbohydrates/adverse effects , Inflammation/complications , Insulin/blood , Polycystic Ovary Syndrome/complications , Dietary Carbohydrates/administration & dosage , Female , Humans , Hyperandrogenism/blood , Hyperandrogenism/complications , Hyperinsulinism/blood , Hyperinsulinism/complications , Inflammation/blood , Insulin Resistance , Polycystic Ovary Syndrome/blood
6.
Crit Rev Food Sci Nutr ; 58(18): 3141-3158, 2018.
Article in English | MEDLINE | ID: mdl-28799803

ABSTRACT

Chronic low-grade systemic inflammation represents a mechanism common to many diseases linked to atherosclerosis-related pathways. There is a growing body of evidence indicating that the combination of food quantity and quality along with genetic susceptibility are able to induce the aberrant activation of innate immune signalling, which initially contributes to chronic low-grade inflammation. Liver represents the central player to inflammatory response. Dietary/metabolic factors contribute to the pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD), the main causes of liver disease in the Western world. Enlargement of the spleen, central organ in regulating the inflammation-related immune response, is commonly seen in patients with of NAFLD, depicting the so called "liver-spleen axis." The aim of this review was to provide an at-a-glance overview of the possible bi-directional mechanisms linking nutrition and inflammation, particularly pinpointing the inflammatory effects stemmed by nutrition on "liver-spleen axis." In particular, the role of unhealthy diet, healthy dietary patterns, such as the Mediterranean diet style, dietary vitamins and micronutrients, such as vitamin D or Magnesium, and Glucagon-Like Peptide-1, a well-known incretin released in response to meal intake, will be discussed. The highly variability of the inflammatory response highlights the role of expert nutritionists in refining methodologies apt to assess nutritional epidemiology and to apply appropriate dietary intervention to counteract diet-induced inflammation mechanisms.


Subject(s)
Inflammation/physiopathology , Liver/physiopathology , Nutritional Status/physiology , Spleen/physiopathology , Diet , Diet, Healthy , Diet, Mediterranean , Food Quality , Gastrointestinal Microbiome/physiology , Genetic Predisposition to Disease , Humans , Inflammation/etiology , Inflammation/genetics , Micronutrients/administration & dosage , Non-alcoholic Fatty Liver Disease/etiology , Non-alcoholic Fatty Liver Disease/physiopathology , Nutritional Status/immunology , Splenomegaly/etiology , Splenomegaly/physiopathology , Vitamin D
7.
Crit Rev Food Sci Nutr ; 58(8): 1294-1309, 2018 May 24.
Article in English | MEDLINE | ID: mdl-27892685

ABSTRACT

The gut regulates glucose and energy homeostasis; thus, the presence of ingested nutrients into the gut activates sensing mechanisms that affect both glucose homeostasis and regulate food intake. Increasing evidence suggest that gut may also play a key role in the pathogenesis of type 2 diabetes which may be related to both the intestinal microbiological profile and patterns of gut hormones secretion. Intestinal microbiota includes trillions of microorganisms but its composition and function may be adversely affected in type 2 diabetes. The intestinal microbiota may be responsible of the secretion of molecules that may impair insulin secretion/action. At the same time, intestinal milieu regulates the secretion of hormones such as GLP-1, GIP, ghrelin, gastrin, somatostatin, CCK, serotonin, peptide YY, GLP-2, all of which importantly influence metabolism in general and in particular glucose metabolism. Thus, the aim of this paper is to review the current evidence on the role of the gut in the pathogenesis of type 2 diabetes, taking into account both hormonal and microbiological aspects.


Subject(s)
Diabetes Mellitus, Type 2/etiology , Gastrointestinal Tract/microbiology , Gastrointestinal Tract/physiology , Gene Expression Regulation , Glucose/metabolism , Humans
8.
Endocrinology ; 158(6): 1527-1532, 2017 06 01.
Article in English | MEDLINE | ID: mdl-28368448

ABSTRACT

Adrenal mass (AM) is a common incidental finding detected during radiological investigations with an estimated incidence of 4%. Subjects with AM do not show any physical signs of adrenal hormonal excess, although they are often insulin resistant. Interestingly, apparently nonfunctioning AMs are often associated with a high prevalence of insulin resistance (IR) and metabolic syndrome. However, it is unclear whether AM develops from a primary IR and compensatory hyperinsulinemia or whether IR is only secondary to the slight cortisol hypersecretion by AM. Further, the degree of IR has been directly reported to correlate to the size of AM, thus allowing one to hypothesize that compensatory hyperinsulinemia to IR could be mitogenic on the adrenal cortex acting through the activation of insulin and insulinlike growth factor 1 receptors. Thus, the aim of the present article is to review the current evidence on the link between AM and compensatory hyperinsulinemia to IR.


Subject(s)
Adrenal Glands/anatomy & histology , Insulin Resistance/physiology , Metabolic Syndrome/etiology , Adrenal Glands/metabolism , Adrenal Glands/pathology , Animals , Humans , Hyperinsulinism/etiology , Hyperinsulinism/pathology , Insulin/metabolism , Metabolic Syndrome/metabolism , Metabolic Syndrome/pathology , Organ Size
9.
Rev Endocr Metab Disord ; 18(3): 323-334, 2017 09.
Article in English | MEDLINE | ID: mdl-28281103

ABSTRACT

Kidney transplant is the treatment of choice for end-stage chronic kidney disease. Kidneys generate 1,25-dihydroxyvitamin D (calcitriol) from 25-hydroxyvitamin D (calcidiol) for circulation in the blood to regulate calcium levels. Transplant patients with low calcidiol levels have an increased risk of metabolic and endocrine problems, cardiovascular disease, type 2 diabetes mellitus, poor graft survival, bone disorders, cancer, and mortality rate. The recommended calcidiol level after transplant is at least 30 ng/mL (75 nmol/L), which could require 1000-3000 IU/d vitamin D3 to achieve. Vitamin D3 supplementation studies have found improved endothelial function and acute rejection episodes. However, since kidney function may still be impaired, raising calcidiol levels may not lead to normal calcitriol levels. Thus, supplementation with calcitriol or an analog, alfacalcidiol, is often employed. Some beneficial effects found include possible improved bone health and reduced risk of chronic allograft nephropathy and cancer.


Subject(s)
Kidney Failure, Chronic/therapy , Kidney Transplantation/adverse effects , Vitamin D Deficiency/etiology , Calcitriol/metabolism , Dietary Supplements , Humans , Kidney/metabolism , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/metabolism , Vitamin D/administration & dosage , Vitamin D/analogs & derivatives , Vitamin D/metabolism , Vitamin D Deficiency/metabolism , Vitamin D Deficiency/prevention & control
10.
Rev Endocr Metab Disord ; 18(2): 215-225, 2017 06.
Article in English | MEDLINE | ID: mdl-28229265

ABSTRACT

Low vitamin D status and obesity have concomitantly reached epidemic levels worldwide. Up to now the direction of the association between low vitamin D status and obesity, the exact mechanisms responsible for this association and the clinical usefulness to increase vitamin D status for reducing adiposity still warrant further evaluation. The aim of the present review was to examine the current evidence linking low vitamin D status and obesity in relation to the role of the nutritionist. On the one side, considering obesity as a causal factor, low sun exposure in obese individuals due to their sedentary lifestyle and less outdoor activity, vitamin D sequestration in adipose tissue, and volumetric dilution of ingested or cutaneously synthesized vitamin D3 in the large fat mass of obese patients, might represent some of the factors playing a major role in the pathogenesis of the low vitamin D status. On the other side, the expression of both vitamin D3 receptors and enzymes responsible for vitamin D3 metabolism in adipocytes depicted a role for the low vitamin D status per se in the development of obesity by modulating adipocyte differentiation and lipid metabolism. Nutritionists need to accurately address the aspects influencing the low vitamin D status in obesity and the vitamin D supplementation in obese individuals.


Subject(s)
Nutritionists , Obesity/etiology , Physician's Role , Vitamin D Deficiency/complications , Adipocytes/drug effects , Adipocytes/metabolism , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Adiposity/drug effects , Adiposity/physiology , Animals , Dietary Supplements , Humans , Lipid Metabolism/drug effects , Obesity/epidemiology , Vitamin D/administration & dosage , Vitamin D/blood , Vitamin D/physiology , Vitamin D Deficiency/blood , Vitamin D Deficiency/diet therapy
11.
Rev Endocr Metab Disord ; 18(3): 273-283, 2017 09.
Article in English | MEDLINE | ID: mdl-28102491

ABSTRACT

In the last decades several studies suggested that vitamin D is involved in the modulation of the reproductive process in women due to the expression of VDR and 1α-hydroxylase in reproductive tissues such as ovary, uterus, placenta, pituitary and hypothalamus. Vitamin D has also a role in the regulation of sex hormone steroidogenesis. Increasing evidence suggests that vitamin D might have a regulatory role in polycystic ovary syndrome (PCOS)-associated symptoms, including ovulatory dysfunction, insulin resistance and hyperandrogenism. Vitamin D deficiency also has been reported to contribute to the pathogenesis of endometriosis due to its immunomodulatory and anti-inflammatory properties. Although most of the studies supported a role of vitamin D in the onset of these diseases, randomized controlled trials to assess the efficacy of vitamin D supplementation have never been performed. In this review we critically discuss the role of vitamin D in female fertility, starting from in vitro and in vivo studies, focusing our attention on the two most frequent causes of female infertility: PCOS and endometriosis.


Subject(s)
Fertility/physiology , Infertility, Female/etiology , Vitamin D/physiology , Dietary Supplements , Endometriosis/blood , Endometriosis/epidemiology , Endometriosis/prevention & control , Female , Fertility/drug effects , Humans , Polycystic Ovary Syndrome/blood , Polycystic Ovary Syndrome/epidemiology , Polycystic Ovary Syndrome/prevention & control , Pregnancy , Sunlight , Vitamin D/administration & dosage , Vitamin D/blood , Vitamin D/pharmacology , Vitamin D Deficiency/blood , Vitamin D Deficiency/complications , Vitamin D Deficiency/diet therapy , Vitamin D Deficiency/epidemiology
12.
Crit Rev Food Sci Nutr ; 57(16): 3472-3488, 2017 Nov 02.
Article in English | MEDLINE | ID: mdl-27030935

ABSTRACT

Increasing evidence suggests that vitamin D exerts multiple effects beyond bone and calcium metabolism. Vitamin D seems to play a role in pancreatic disease, including type 1 and type 2 diabetes mellitus as well as pancreatic cancer. Vitamin D's immune-modulatory action suggests that it could help prevent type 1 diabetes. In type 2 diabetes, vitamin D may influence ß-cell function, insulin sensitivity, and systematic inflammation-all characteristic pathways of that disease. Data from observational studies correlated vitamin D deficiency with risk of type 1 and type 2 diabetes. Prospective and ecological studies of pancreatic cancer incidence generally support a beneficial effect of higher 25-hydroxyvitamin D concentration as well as inverse correlations between UVB dose or exposure and incidence and/or mortality rate of pancreatic cancer. This review discusses the literature regarding vitamin D's role in risk of diabetes and pancreatic cancer. The results to date generally satisfy Hill's criteria for causality regarding vitamin D and incidence of these pancreatic diseases. However, large randomized, blinded, prospective studies are required to more fully evaluate the potential therapeutic role of vitamin D in preventing pancreatic diseases.


Subject(s)
Diabetes Mellitus, Type 2/epidemiology , Pancreatic Neoplasms/epidemiology , Sunlight , Vitamin D/biosynthesis , Vitamin D/therapeutic use , Diabetes Mellitus, Type 2/prevention & control , Humans , Pancreatic Neoplasms/prevention & control , Prospective Studies , Vitamin D Deficiency , Vitamins
13.
Rev Endocr Metab Disord ; 18(2): 207-214, 2017 06.
Article in English | MEDLINE | ID: mdl-27645613

ABSTRACT

The aim of this review is to provide a general overview of the possible associations among the vitamin D status, air pollution and obesity. Sunlight exposure accounts in humans for more than 90 % of the production of vitamin D. Among emerging factors influencing sunlight-induced synthesis of vitamin D, prospective and observational studies proved that air pollution constitutes an independent risk factor in the pathogenesis of vitamin D hypovitaminosis. In addition, environmental pollutants can affect risk of obesity when inhaled, in combination with unhealthy diet and lifestyle. In turn, obesity is closely associated with a low vitamin D status and many possible mechanisms have been proposed to explain this association. The associations of air pollution with low vitamin D status on the hand and with obesity on the other hand, could provide a rationale for considering obesity as a further link between air pollution and low vitamin D status. In this respect, a vicious cycle could operate among low vitamin D status, air pollution, and obesity, with additive detrimental effects on cardio-metabolic risk in obese individuals. Besides vitamin D supplementation, nutrient combination, used to maximize the protective effects against air pollution, might also contribute to improve the vitamin D status by attenuating the "obesogen" effects of air pollution.


Subject(s)
Air Pollution/adverse effects , Nutritional Status/physiology , Obesity/etiology , Vitamin D Deficiency/complications , Air Pollution/statistics & numerical data , Humans , Obesity/epidemiology , Risk Factors , Sunlight , Vitamin D/blood , Vitamin D/physiology , Vitamin D Deficiency/epidemiology
14.
Arch Toxicol ; 91(1): 97-107, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27425218

ABSTRACT

The objective was to provide the current state of the art regarding the role of vitamin D in chronic diseases (osteoporosis, cancer, cardiovascular diseases, dementia, autism, type 1 and type 2 diabetes mellitus, male and female fertility). The document was drawn up by panelists that provided their contribution according to their own scientific expertise. Each scientific expert supplied a first draft manuscript on a specific aspect of the document's topic that was subjected to voting by all experts as "yes" (agreement with the content and/or wording) or "no" (disagreement). The adopted rule was that statements supported by ≥75 % of votes would be immediately accepted, while those with <25 % would be rejected outright. Others would be subjected to further discussion and subsequent voting, where ≥67 % support or, in an eventual third round, a majority of ≥50 % would be needed. This document finds that the current evidence support a role for vitamin D in bone health but not in other health conditions. However, subjects with vitamin D deficiency have been found to be at high risk of developing chronic diseases. Therefore, although at the present time there is not sufficient evidence to recommend vitamin D supplementation as treatment of chronic diseases, the treatment of vitamin D deficiency should be desiderable in order to reduce the risk of developing chronic diseases.


Subject(s)
Evidence-Based Medicine , Osteoporosis/prevention & control , Vitamin D Deficiency/diet therapy , Vitamin D/therapeutic use , Animals , Autism Spectrum Disorder/epidemiology , Autism Spectrum Disorder/etiology , Autism Spectrum Disorder/prevention & control , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Cardiovascular Diseases/prevention & control , Dementia/epidemiology , Dementia/etiology , Dementia/prevention & control , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 1/etiology , Diabetes Mellitus, Type 1/prevention & control , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/etiology , Diabetes Mellitus, Type 2/prevention & control , Female , Humans , Infertility, Female/epidemiology , Infertility, Female/etiology , Infertility, Female/prevention & control , Infertility, Male/epidemiology , Infertility, Male/etiology , Infertility, Male/prevention & control , Male , Neoplasms/epidemiology , Neoplasms/etiology , Neoplasms/prevention & control , Osteoporosis/epidemiology , Osteoporosis/etiology , Practice Guidelines as Topic , Risk , Vitamin D Deficiency/physiopathology
15.
Clin Nutr ; 36(1): 293-301, 2017 02.
Article in English | MEDLINE | ID: mdl-26732027

ABSTRACT

BACKGROUND & AIMS: Nutrition is the major environmental factor that influences the risk of developing pathologies, such as obesity. Although a number of recent reviews pinpoint a protective effects of milk on body weight and obesity related co-morbidities, an inaccurate estimate of milk might contribute to hamper its beneficial effects on health outcomes. Seven-day food records provide prospective food intake data, reducing recall bias and providing extra details about specific food items. Milk intake stimulates the somatotropic axis at multiple levels by increasing both growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. On the other hand, obesity is associated with reduced spontaneous and stimulated GH secretion and basal IGF-1 levels. Aim of this study was to evaluate the milk consumption by using the 7-days food record in obese individuals and to investigate the association between milk intake and GH secretory status in these subjects. METHODS: Cross-sectional observational study carried out on 281 adult individuals (200 women and 81 men, aged 18-74 years) with moderate-severe obesity (BMI 35.2-69.4 kg/m2). Baseline milk intake data were collected using a 7 day food record. Anthropometric measurements and biochemical profile were determined. The GH/IGF-1 axis was evaluated by peak GH response after GHRH + ARGININE and IGF-1 standard deviation score (SDS). RESULTS: The majority of individuals (72.2%) reported consuming milk; 250 mL low-fat milk was the most frequently serving of milk consumed, while no subjects reported to consume whole milk. Milk consumers vs no milk consumers presented the better anthropometric measurements and metabolic profile. At the bivariate proportional odds ratio model, after adjusting for BMI, age and gender, milk consumption was associated the better GH status (OR = 0.60; p < 0.001). Among milk consumers, subjects consuming 250 mL reduced-fat milk vs 250 mL low-fat milk presented the better anthropometric measurements and metabolic profile. At the bivariate proportional odds ratio model, after adjusting for BMI, age and gender, the consume of 250 mL reduced-fat milk was associated better GH status (OR = 0.54; p = 0.003). CONCLUSIONS: A novel positive association between milk consumption, GH status, and metabolic profile in obese individuals was evidenced. Regardless of the pathogenetic mechanisms, this novel association might be relevant in a context where commonly obese individuals skip breakfast, and suggests the need of a growing cooperation between Nutritionists and Endocrinologists in the management of the obese patients.


Subject(s)
Human Growth Hormone/blood , Metabolome , Milk/chemistry , Obesity, Morbid/blood , Adolescent , Adult , Aged , Animals , Body Mass Index , Cholesterol/blood , Cross-Sectional Studies , Diet Records , Dietary Fats/administration & dosage , Dietary Fats/analysis , Female , Human Growth Hormone/metabolism , Humans , Insulin-Like Growth Factor I/metabolism , Male , Metabolic Syndrome/blood , Middle Aged , Nutrition Assessment , Nutritional Status , Prospective Studies , Risk Factors , Triglycerides/blood , Young Adult
17.
J Ovarian Res ; 9(1): 72, 2016 Nov 01.
Article in English | MEDLINE | ID: mdl-27802832

ABSTRACT

In 1963 George Mathé announced to the world that he had cured a patient of leukaemia by means of a bone-marrow transplant. Since than much progress has been made and nowadays Hematopoietic Stem Cell Transplantation (HSCT) is considered the most effective treatment of numerous severe haematological diseases. Gynaecological complications in HSCT women represent a serious concern for these patients, but often underestimated by clinicians in the view of Overall Survival. The main gynaecological complications of HSCT are represented by: premature ovarian failure (POF), thrombocytopenia-associated menorrhagia, genital symptoms or sexual problems in course of chronic GVHD (cGVHD), osteoporosis, secondary solid tumours due to immunosuppressive drugs to treat cGVHD and severity of cGVHD, and fertility and pregnancy issues. In particular fertility-related issues are always more relevant for patients, whose life expectation is constantly growing up after HSCT.Thus, taking care of a patient undergoing HSCT should primarily include gynaecological evaluation, even before conditioning regimen or chemotherapy for the underlying malignancy, as, in our opinion, it is of great importance to ensure a complete diagnostic work-up and intervention options to guarantee maximum reproductive health and a better quality of life in HSCT women.The present review aims at describing principal features of the aforementioned gynaecological complications of HSCT, and to define, on the basis of current international literature, a specific protocol for the prevention, diagnosis, management and follow-up of gynaecological complications of both autologous and heterologous transplantation, before and after the procedure.


Subject(s)
Female Urogenital Diseases/diagnosis , Female Urogenital Diseases/etiology , Female Urogenital Diseases/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Disease Management , Female , Fertility , Fertility Preservation , Graft vs Host Disease/diagnosis , Graft vs Host Disease/etiology , Graft vs Host Disease/therapy , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Neoplasms, Second Primary/diagnosis , Neoplasms, Second Primary/etiology , Neoplasms, Second Primary/therapy , Osteoporosis/diagnosis , Osteoporosis/etiology , Osteoporosis/therapy , Pregnancy
18.
Int J Endocrinol ; 2016: 3058393, 2016.
Article in English | MEDLINE | ID: mdl-27688754

ABSTRACT

A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.

19.
Minerva Endocrinol ; 41(4): 509-15, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27600645

ABSTRACT

Adulthood and childhood obesity is rapidly becoming an epidemic problem and it has a short and long-term impact on health. Short-term consequences are mostly represented by psychological effects; in fact obese children have more chances to develop psychological or psychiatric problems than non-obese children. The main long-term effect is represented by the fact that childhood obesity continues into adulthood obesity and this results in negative effects in young adult life, since obesity increases the risk to develop morbidity and premature mortality. The obesity-related diseases are mostly represented by hypertension, type 2 diabetes, dyslipidemia, cardiovascular diseases. Medical treatment should be discouraged in childhood because of the side effects and it should be only reserved for obese children with related medical complications. Lifestyle changes should be encouraged in both adulthood and childhood obesity. This review focuses on the management of obesity both in adulthood and in childhood, paying particular attention to lifestyle changes that should be recommended.


Subject(s)
Life Style , Obesity/therapy , Pediatric Obesity/therapy , Adult , Child , Exercise , Humans , Overweight/therapy , Young Adult
20.
Article in English | MEDLINE | ID: mdl-27483295

ABSTRACT

Growing evidence suggests the causal link between the endocrine-disrupting chemicals (EDCs) and the global obesity epidemics, in the context in the so-called "obesogenic environment". Dietary intake of contaminated foods and water, especially in association with unhealthy eating pattern, and inhalation of airborne pollutants represent the major sources of human exposure to EDCs. This is of particular concern in view of the potential impact of obesity on chronic non-transmissible diseases, such as type 2 diabetes, cardiovascular disease, and hormone-sensitive cancers. The key concept is the identification of adipose tissue not only as a preferential site of storage of EDCs, but also as an endocrine organ and, as such, susceptible to endocrine disruption. The timing of exposure to EDCs is critical to the outcome of that exposure, with early lifetime exposures (e.g., fetal or early postnatal) particularly detrimental because of their permanent effects on obesity later in life. Despite that the mechanisms operating in EDCs effects might vary enormously, this minireview is aimed to provide a general overview on the possible association between the pandemics of obesity and EDCs, briefly describing the endocrine mechanisms linking EDCs exposure and latent onset of obesity.


Subject(s)
Endocrine Disruptors/adverse effects , Environmental Pollutants/adverse effects , Obesity/chemically induced , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Biomarkers/metabolism , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/genetics , Diabetes Mellitus, Type 2/chemically induced , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/genetics , Drinking Water , Endocrine Disruptors/analysis , Environmental Exposure/adverse effects , Environmental Exposure/analysis , Environmental Pollutants/analysis , Feeding Behavior , Food Contamination , Gene Expression Regulation , Humans , Obesity/epidemiology , Obesity/genetics , Obesity/physiopathology , Water Pollution, Chemical/adverse effects , Water Pollution, Chemical/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...